Probiotics are a multibillion dollar international industry, but new research Wednesday showed they don’t help children recover from stomach flu any better than a placebo. The results of two randomized clinical trials — which came to the same conclusions — were published in the New England Journal of Medicine. “Probiotics had no effect on the children,” said co-author Phillip Tarr, a professor of pediatrics at Washington University in St. Louis, adding that the findings were “not ambiguous.””Parents are better off saving their money and using it to buy more fresh fruits and vegetables for their children.” Probiotics are surging in popularity, with the global market predicted to expand from $37 billion in 2015 to $64 billion by 2023, according to the report. Five of 12 leading medical groups worldwide currently endorse their use, as a way to promote gut health by restoring intestinal flora, building up so-called “good bacteria” in children’s bodies. Those recommending probiotics include the European Society for Pediatric Gastroenterology Hepatology and Nutrition, the Cincinnati Children’s Hospital Medical Center and the Royal Australian College of General Practitioners. For one study in the United States, researchers tested a popular brand of probiotic, sold under the name Culturelle. A total of 971 children between three months and four years old were enrolled in the study. All sought emergency room care for gastroenteritis, an intestinal condition that can be caused by a virus or a bacterial infection — with symptoms including vomiting and diarrhea. The children were randomly assigned to either receive a five-day course of a placebo or Culturelle, which contains the bacterium Lactobacillus rhamnosus GG. A pack of 30, promoted as a “number one pediatrician-recommended daily probiotic,” costs around $20. But researchers found that kids who took the probiotic showed no difference in the length of illness or the severity of symptoms, compared to kids given a sugar pill. The second study, carried out in Canada, used a product called Lacidofil Strong, containing Lactobacillus rhamnosus R0011 and L. helveticus R0052. More than 800 children were randomized to receive either a five-day course or a placebo. The difference was so slight, researchers said it was not statistically significant. “Moderate-to-severe gastroenteritis within 14 days after enrollment occurred in 108 of 414 participants (26.1 percent) who were assigned to probiotics and 102 of 413 participants (24.7 percent) who were assigned to placebo,”
